As per the research report, the size of the Asia Pacific Intravenous Ibuprofen Market was valued at USD 1.65 billion in 2022 and estimated to be growing at a CAGR of 20.6%, to reach USD 4.22 billion by 2027 during the forecast period 2022 to 2027.
The APAC IV ibuprofen market is driven by pharmaceutical and biopharmaceutical production. This rise in production is due to the rising prevalence of chronic diseases, which requires easy availability of ibuprofen across the APAC region. 80% of individuals suffer from postoperative pain in the postoperative period, with almost all describing it as moderate to severe. IV ibuprofen has many advantages over pain-relieving drugs, such as easy availability, cost-effective and quicker results. In addition, side effects of opioid analgesics such as respiratory depression, allergic reactions, sedation, and gastrointestinal events can be avoided using ibuprofen. Several other advantages associated with intravenous ibuprofen combined with rapid results and efficient drug delivery are further expected to help build the necessary brand positioning for the drug.
The major drivers of the market include a rise in sports injury, rising disposable income in industrialized economies, growing research and development activities for the development of innovative drugs, and increasing incidence of chronic illness such as respiratory disorders, heart disease, obesity, and asthma in the region. The general rise in the number of surgeries and rising awareness about advanced therapeutic drugs associated with operative and postoperative pain drive market growth for intravenous ibuprofen. Additionally, increasing private sector investments being inflexed into healthcare and improving medical infrastructure will boost the development of the market.
Moreover, as the demand for opioid analgesics is decreasing due to difficulty in the legalization process, which is lengthy and requires numerous clinical trials before product launch, thus, the subsequent increase in demand for alternative pharmacy products such as intravenous ibuprofen is increasing in the APAC region. Adverse side effects of ibuprofen and an increase in the price of raw materials would be challenged by the market's growth.
This research report on the APAC Intravenous Ibuprofen Market has been segmented and sub-segmented into the following categories:
By Age Group:
Geographically, the Chinese intravenous ibuprofen market is anticipated to remain the most dominant region during the analysis period due to the widespread adoption of IV Ibuprofen to treat various conditions. Other factors such as the large population, well-developed pharmaceutical industry, and accessible regulatory authorities in the region will drive the market in the years to come. In 2020, the pharmaceutical industry in China generated a revenue of about 195 billion USD. A considerable amount of the total income can be allotted to producing opioid and non-opioid drugs.
The Australia intravenous ibuprofen market is estimated to increase during the projected period, owing to wide acceptance of IV Ibuprofen, raising awareness of non-steroidal anti-inflammatory drugs, and shifting trend towards the intravenous mode of drug delivery. Although, extra caution and monitoring are required in patients with extended use and those with significant co-morbidities, including those undergoing cardiac or vascular procedures.
India intravenous ibuprofen market will also have steady growth, mainly due to the development of the pharmaceutical industry. The domestic pharmaceutical sector's annual turnover reached over 22 billion U.S. dollars in 2020. In 2018, the Indian pharmaceutical market valued 20 billion U.S. dollars. However, other factors such as the increasing prevalence of chronic diseases and the resulting rise in the demand for advanced therapeutic will affect the market growth in this region.
KEY MARKET PLAYERS
The top companies leading in the APAC Intravenous Ibuprofen Market profiled in the report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc., CSL Limited, Sandor Medicaids Pvt Ltd., Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., PT. Soho Industri Pharmasi, and Laboratorios Valmorca, C.A.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org